These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 17681244)

  • 1. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma.
    Oehler-Jänne C; Seifert B; Lütolf UM; Studer G; Glanzmann C; Ciernik IF
    Brachytherapy; 2007; 6(3):218-26. PubMed ID: 17681244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
    Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M
    Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
    Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
    Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens.
    Mayer A; Nemeskéri C; Petneházi C; Borgulya G; Varga S; Naszály A
    Strahlenther Onkol; 2004 Apr; 180(4):209-15. PubMed ID: 15057431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical results of medium dose rate brachytherapy combined with external beam radiotherapy in the treatment of advanced cervical carcinoma.
    Ordeanu C; Coza O; Gavris S; Todor N; Szilagy E; Bako M; Cernea V; Ghilezan N; Nagy V
    J BUON; 2007; 12(2):221-6. PubMed ID: 17600876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of failure and outcome in patients with carcinoma of the anal margin.
    Khanfir K; Ozsahin M; Bieri S; Cavuto C; Mirimanoff RO; Zouhair A
    Ann Surg Oncol; 2008 Apr; 15(4):1092-8. PubMed ID: 18231838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix.
    Nakano T; Kato S; Ohno T; Tsujii H; Sato S; Fukuhisa K; Arai T
    Cancer; 2005 Jan; 103(1):92-101. PubMed ID: 15540233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endobronchial brachytherapy and optimization of local disease control in medically inoperable non-small cell lung carcinoma: a matched-pair analysis.
    Mantz CA; Dosoretz DE; Rubenstein JH; Blitzer PH; Katin MJ; Garton GR; Nakfoor BM; Siegel AD; Tolep KA; Hannan SE; Dosani R; Feroz A; Maas C; Bhat S; Panjikaran G; Lalla S; Belani K; Ross RH
    Brachytherapy; 2004; 3(4):183-90. PubMed ID: 15607149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
    Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
    Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis.
    Rossi PJ; Jani AB; Horowitz IR; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):134-8. PubMed ID: 17855014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study).
    Moureau-Zabotto L; Ortholan C; Hannoun-Levi JM; Teissier E; Cowen D; Salem N; Lemanski C; Ellis S; Resbeut M
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e135-42. PubMed ID: 23195780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soft tissue sarcomas treated with postoperative external beam radiotherapy with and without low-dose-rate brachytherapy.
    Andrews SF; Anderson PR; Eisenberg BL; Hanlon AL; Pollack A
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):475-80. PubMed ID: 15145165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
    Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
    Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
    Ferrigno R; Nakamura RA; Dos Santos Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV; Filho WJ; Lopes A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1136-42. PubMed ID: 15752894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer first results of the randomized Budapest boost trial.
    Polgár C; Fodor J; Orosz Z; Major T; Takácsi-Nagy Z; Mangel LC; Sulyok Z; Somogyi A; Kásler M; Németh G
    Strahlenther Onkol; 2002 Nov; 178(11):615-23. PubMed ID: 12426672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment results of 59 young patients with nasopharyngeal carcinoma.
    Selek U; Ozyar E; Ozyigit G; Varan A; Buyukpamukcu M; Atahan IL
    Int J Pediatr Otorhinolaryngol; 2005 Feb; 69(2):201-7. PubMed ID: 15656953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome with interstitial brachytherapy boost in the treatment of women with early-stage breast cancer.
    Neumanova R; Petera J; Frgala T; Dusek L; Jarkovsky J; Kuricka R
    Neoplasma; 2007; 54(5):413-23. PubMed ID: 17688371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.